1. Name Of The Medicinal Product
Urispas 200 mg Film-coated Tablets
2. Qualitative And Quantitative Composition
Each Urispas tablet contains flavoxate hydrochloride 200 mg.
For excipients, see 6.1.
3. Pharmaceutical Form
Film-coated tablet.
White, film-coated tablets embossed with 'F 200'.
4. Clinical Particulars
4.1 Therapeutic Indications
Urispas is indicated for the symptomatic relief of dysuria, urgency, nocturia, vesical supra-pubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethro-cystitis and urethrotrigonitis.
In addition, the preparation is indicated for the relief of vesico-urethral spasms due to catheterisation, cystoscopy or indwelling catheters; prior to cystoscopy or catheterisation; sequelae of surgical intervention of the lower urinary tract.
4.2 Posology And Method Of Administration
For oral administration.
Adults (including the elderly):
The recommended adult dosage is one tablet three times a day for as long as required.
Children:
Urispas tablets are not recommended for children under 12 years of age.
4.3 Contraindications
The following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastro-intestinal haemorrhage and obstructive uropathies of the lower urinary tract.
Hypersensitivity to flavoxate hydrochloride or to any of the excipients of Urispas 200.
4.4 Special Warnings And Precautions For Use
Urispas should be used with caution in patients with suspected glaucoma, especially closed angle cases and in patients with serious, uncontrolled, obstructive disorders of the lower urinary tract.
Where evidence of urinary infection is present, appropriate anti-infective therapy should be instituted concomitantly.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicine.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
None known.
4.6 Pregnancy And Lactation
Since there is no evidence of the drug's safety in human pregnancy, nor any evidence from animal work that it is free from hazard, Urispas should be avoided in pregnancy unless there is no safer alternative. It is not known whether flavoxate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Urispas is administered during breast-feeding.
4.7 Effects On Ability To Drive And Use Machines
In the event of drowsiness, blurred vision and vertigo, the patient should not operate a motor vehicle or machinery.
4.8 Undesirable Effects
In clinical trials comparing Urispas with other antispasmodic agents, the incidence of side-effects was low. The following adverse reactions have been observed:
Blood and lymphatic disorders: Eosinophilia, leukopenia.
Immune system disorders: Hypersensitivity reactions
Nervous system disorders: Drowsiness, dizziness, headache, mental confusion (especially in the elderly), nervousness, vertigo.
Eye disorders: Blurred vision, disturbances in eye accommodation, increased ocular tension.
Cardiac disorders: Palpitations, tachycardia.
Gastrointestinal disorders: Diarrhoea, dry mouth, dyspepsia, dysphagia, nausea, vomiting.
Skin and subcutaneous tissue disorders: Angioedema, urticaria, erythema, rash, pruritis
Renal and urinary disorders: Dysuria.
General disorders: Fatigue, hyperpyrexia.
4.9 Overdose
No case of overdose has been reported. The signs and symptoms of significant overdosing of Urispas are predicted to be similar to those of other anticholinergics. These generally involve the autonomic nerve endings and the brain and include nausea, vomiting, flushing, dilated pupils, dry mouth and tongue, hot dry skin, fever, sinus tachycardia, hypertension, ataxia, nystagmus, drowsiness, delirium, agitation and visual hallucinations. Uncommonly, systemic features of anticholinergics toxicity include myoclonic jerking, coma, convulsions, cardiac conduction abnormalities and dysrhythmias, cardiovascular collapse, paralytic ileus, urinary retention.
Consider activated charcoal if a patient presents within one hour of ingestion of a potentially toxic amount. Alternatively the role of gastric lavage should be considered in adults presenting within 1 hour of a potentially life-threatening overdose.
Treatment is supportive and observation for 6 hours after ingestion, without other specific treatment, will be sufficient for the majority of patients.
Because strategies for the management of overdose are continually evolving, it is advisable to contact a poison control centre to determine the latest recommendations for the management of an overdose.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Pharmacotherapeutic Group: Urinary antispasmodics – Flavoxate
ATC code: G04BD02
Flavoxate hydrochloride (and its main metabolite methyl flavone carboxylic acid, MFCA) is an antispasmodic selective to the urinary tract. In animal and human studies, flavoxate hydrochloride has been shown to have a direct antispasmodic action on smooth muscle fibres.
The mechanism of action involves intracellular cyclic AMP accumulation and calcium blocking activity. It inhibits bladder contractions induced by various agonists or by electrical stimulation and inhibits the frequency of bladder voiding contractions. It increases bladder volume capacity, reduces the threshold and micturition pressure.
In addition, animal studies have shown flavoxate hydrochloride to have analgesic and local anaesthetic properties.
Flavoxate does not significantly affect cardiac or respiratory functions.
5.2 Pharmacokinetic Properties
Oral studies in man have indicated that flavoxate is readily absorbed from the intestine and converted, to a large extent, almost immediately to MFCA.
Following an IV dose (equimolar to 100 mg), the following parameters were calculated for flavoxate: T½ 83.3 mins: apparent volume of distribution 2.89 l/kg. The apparent distribution of MFCA was 0.20 l/kg. No free flavoxate was found in urine (24 hours). However, 47% of the dose was excreted as MFCA.
Following single oral dosing to volunteers of 200 mg and 400 mg flavoxate, almost no free flavoxate was detected in the plasma. The peak level of MFCA was attained at 30-60 mins after the 200 mg dose and at around two hours following the 400 mg dose. The AUC for the 400 mg dose was approximately twice as large as the AUC for the 200 mg dose. About 50% of the dose was excreted as MFCA within 12 hours; most being excreted within the first 6 hours.
After repeated oral dosing (200 mg, TDS, 7 days) the cumulative excretion of metabolites stabilised at 60% of the dose on the third day remaining almost unchanged after one week.
5.3 Preclinical Safety Data
None stated.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Tablet Core:
Lactose
Sodium starch glycollate
Povidone
Talc
Magnesium stearate
Cellulose microcrystalline
Tablet Coating:
Hypromellose
Cellulose microcrystalline
Macrogol 6000
Macrogol stearate
Magnesium stearate
Titanium dioxide (E171)
6.2 Incompatibilities
None known.
6.3 Shelf Life
3 years.
6.4 Special Precautions For Storage
Do not store above 30°C. Keep blister strips in the outer carton.
6.5 Nature And Contents Of Container
PVC / aluminium blister strips in pack sizes of 84, 90, 100 and 250 tablets.
Not all pack sizes may be marketed.
6.6 Special Precautions For Disposal And Other Handling
Not applicable.
7. Marketing Authorisation Holder
Recordati Pharmaceuticals Limited
Isis House
43 Station Road
Henley-on-Thames
Oxfordshire RG9 1AT
United Kingdom
8. Marketing Authorisation Number(S)
PL 25046/0006
9. Date Of First Authorisation/Renewal Of The Authorisation
14th August, 2007
10. Date Of Revision Of The Text
09 June 2010
No comments:
Post a Comment